FUJIFILM Diosynth Biotechnologies vs Northway Biotech: CDMO Comparison
How does FUJIFILM Diosynth Biotechnologies compare to Northway Biotech for AAV manufacturing?
Side-by-side comparison of FUJIFILM Diosynth Biotechnologies and Northway Biotech on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- FUJIFILM Diosynth Biotechnologies has materially broader EMA GMP coverage (29 active certificates vs 8) — stronger EU footprint.
- FUJIFILM Diosynth Biotechnologies maintains 6 MHRA / UK GMP certificates; Northway Biotech does not.
On a 13-modality CDMO landscape, both FUJIFILM Diosynth Biotechnologies and Northway Biotech qualify as AAV manufacturers; FUJIFILM Diosynth Biotechnologies carries the higher composite Signal Score for AAV programs in this comparison.
What to evaluate for AAV programs
Both FUJIFILM Diosynth Biotechnologies and Northway Biotech qualify as AAV CDMOs. When choosing between them for AAV programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
Platform & scale
Suspension processes scale better than adherent (HEK293) for commercial volumes. Confirm the CDMO's largest validated bioreactor scale and serotype track record.
Capsid quality
Full/empty capsid ratio and aggregate control drive potency and safety. Ask about AUC, anion-exchange separation, and the analytics package for capsid characterization.
Regulatory readiness
For programs heading to BLA, a strong FDA inspection history and EMA/MHRA GMP coverage matter — both are shown above and on each profile.
Capacity & timelines
AAV manufacturing slots can be constrained. Weigh the capacity signal and clinical-program load before committing.
Frequently asked: FUJIFILM Diosynth Biotechnologies vs Northway Biotech
How does FUJIFILM Diosynth Biotechnologies compare to Northway Biotech for AAV manufacturing?
On CDMO Signal's composite Signal Score, FUJIFILM Diosynth Biotechnologies is 85/100 and Northway Biotech is 81/100; European coverage is 35 active EMA+MHRA certificates for FUJIFILM Diosynth Biotechnologies vs 8 for Northway Biotech. Both are tracked in the CDMO Signal directory as AAV CDMOs. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.
How do FUJIFILM Diosynth Biotechnologies and Northway Biotech compare on European GMP coverage?
FUJIFILM Diosynth Biotechnologies holds 29 active EMA GMP certificates and 6 MHRA / UK certificates. Northway Biotech holds 8 active EMA GMP certificates and 0 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is better for AAV manufacturing — FUJIFILM Diosynth Biotechnologies or Northway Biotech?
Both FUJIFILM Diosynth Biotechnologies and Northway Biotech are tagged as AAV CDMOs in our directory, so both are credible options for AAV programs. The most important differentiator for AAV selection is typically platform & scale: Suspension processes scale better than adherent (HEK293) for commercial volumes. Confirm the CDMO's largest validated bioreactor scale and serotype track record. Review each CDMO's profile and inspection record before shortlisting.
What does the Signal Score gap mean in practice?
FUJIFILM Diosynth Biotechnologies carries a Signal Score of 85/100 and Northway Biotech carries 81/100 — essentially tied for FUJIFILM Diosynth Biotechnologies. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →